Edition:
United Kingdom

ImmuCell Corp (ICCC.OQ)

ICCC.OQ on NASDAQ Stock Exchange Capital Market

6.50USD
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
$6.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,352
52-wk High
$9.25
52-wk Low
$5.29

Latest Key Developments (Source: Significant Developments)

Immucell Sees Q2 Product Sales $3 Mln Versus $1.8 Mln
Tuesday, 10 Jul 2018 

July 10 (Reuters) - ImmuCell Corp ::IMMUCELL ANNOUNCES PRELIMINARY SALES RESULTS FOR SECOND QUARTER OF 2018.IMMUCELL CORP - SEES Q2 PRODUCT SALES $3 MILLION VERSUS $1.8 MILLION.  Full Article

ImmuCell Q1 Loss Per Share $0.04
Monday, 14 May 2018 

May 14 (Reuters) - ImmuCell Corp ::IMMUCELL ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018.Q1 LOSS PER SHARE $0.04.  Full Article

ImmuCell Corp Announces Pricing Of $3 Mln Public Offering Of Common Shares
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Immucell Corp ::IMMUCELL CORPORATION ANNOUNCES PRICING OF $3 MILLION PUBLIC OFFERING OF COMMON SHARES.IMMUCELL CORP - UNDERWRITTEN PUBLIC OFFERING OF 417,807 SHARES OF STOCK AT A PRICE TO PUBLIC OF $7.30 PER SHARE.IMMUCELL CORP - ALSO ANNOUNCED ESTIMATED REVENUES FOR TWELVE-MONTH PERIOD ENDED NOVEMBER 30, 2017 EXPECTED TO INCREASE BY 9% TO $10.2 MILLION.  Full Article

Immucell Q3 loss per share $0.07
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Immucell Corp ::Immucell announces financial results for third quarter of 2017.Q3 loss per share $0.07.Immucell - ‍during 3-month period ended Sept 30, 2017, total product sales were just over $2 million versus just under $2 million during same quarter of 2016​.  Full Article

Immucell Q4 sales fell 18 pct
Thursday, 9 Feb 2017 

Immucell Corp : Immucell announces preliminary 2016 financial results .Q4 sales fell 18 percent to $2.2 million.  Full Article

Immucell Corp sees FDA approval for Mast Out in 2019
Tuesday, 11 Oct 2016 

Immucell Corp :Immucell Corp - U.S. FDA approval for co's product Mast Out anticipated in 2019, allowing for two, six-month reviews of cmc technical section by FDA.  Full Article

No consensus analysis data available.